S&P 500   3,800.00
DOW   30,978.05
QQQ   315.86
S&P 500   3,800.00
DOW   30,978.05
QQQ   315.86
S&P 500   3,800.00
DOW   30,978.05
QQQ   315.86
S&P 500   3,800.00
DOW   30,978.05
QQQ   315.86
Log in

Epigenomics Stock Forecast, Price & News

0.00 (0.00 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $33.00
50-Day Range
MA: $17.71
52-Week Range
Now: $33.00
Average Volume1,054 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA and, HCCBloodTest, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma (HCC) The comapny was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo Gut on April 30, 1997 and is headquartered in Berlin, Germany.


Overall MarketRank

0.56 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Diagnostics & Research
Phone(493) 024-3450



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable
0.00 (0.00 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EPGNY News and Ratings via Email

Sign-up to receive the latest news and ratings for EPGNY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Epigenomics (OTCMKTS:EPGNY) Frequently Asked Questions

How has Epigenomics' stock been impacted by Coronavirus?

Epigenomics' stock was trading at $7.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EPGNY shares have increased by 337.1% and is now trading at $33.00.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than Epigenomics?

Wall Street analysts have given Epigenomics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Epigenomics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Epigenomics?

Epigenomics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 400 shares, a decrease of 76.5% from the December 15th total of 1,700 shares. Based on an average trading volume of 500 shares, the days-to-cover ratio is presently 0.8 days.
View Epigenomics' Short Interest

Who are some of Epigenomics' key competitors?

Who are Epigenomics' key executives?

Epigenomics' management team includes the following people:
  • Gregory K. Hamilton, Chief Executive Officer
  • Jorge A. Garces, President & Chief Scientific Officer
  • Albert Weber, Executive Vice President-Finance
  • Frederic Hilke, Media & Investor Relations Contact
  • Annett Dietrich, Manager-Human Resources

What is Epigenomics' stock symbol?

Epigenomics trades on the OTCMKTS under the ticker symbol "EPGNY."

How do I buy shares of Epigenomics?

Shares of EPGNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Epigenomics' stock price today?

One share of EPGNY stock can currently be purchased for approximately $33.00.

What is Epigenomics' official website?

The official website for Epigenomics is www.epigenomics.com.

How can I contact Epigenomics?

The company can be reached via phone at (493) 024-3450.

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.